Portola Pharmaceuticals Inc. recently announced it has submitted a Marketing Authorization Application (MAA) for IndexXa to the European Medicines Agency, noting that the validation period has been completed and it has been accepted for review. Read More »

AbbVie recently released new data from its Phase 3 GARNET study involving the combination of VIEKIRAX and EXVIERA that shows significant response rates after only eight weeks of the medication. Read More »

AcelRx Pharmaceuticals Inc. recently presented the subgroup analysis from the SAP301 clinical study by board-certified plastic surgeon and AcelRx clinical investigator Dr. Shankar Lakshman at the American Society of Plastic Surgeons (ASPS) annual meeting. Read More »

Johnson & Johnson recently made a five-year commitment to aid the United Nations Sustainable Development Goals in its mission to see the improvement of the health and well-being of people worldwide. Read More »

Neuraltus Pharmaceuticals Inc. recently announced that it has begun a second Phase 2 trial of NP001, its investigational treatment designed for patients who have amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease. Read More »

Akcea Therapeutics, an Ionis Pharmaceuticals subsidiary, recently reported that significant results from two clinical studies of INOIS-APO(a) and IONIS-APO(a)-L have been published in The Lancet. Read More »

Lannett Company Inc. announced that the U.S. Food and Drug Administration (FDA) recently approved its Abbreviated New Drug Application (ANDA) for Buprenorphine and Naloxone Sublingual Tablets for the dosing options of 2 mg/0.5 mg and 8 mg/2mg. Read More »

Upsher-Smith Laboratories Inc. recently announced it has entered into an exclusive agreement with an emerging pharmaceutical company for the marketing and distribution of a generic central nervous system (CNS) product. Read More »

Valeant Pharmaceuticals International has appointed of Paul S. Herendeen as the company’s new EVP of Finance. Read More »

Crown BioScience recently reported that it is currently developing a non-alcoholic fatty liver disease (NAFLD) model. Read More »

As debate rages over drug prices, one of the country’s largest pharmacy benefit managers is touting biosimilars as a way of achieving significant savings over the next five years. Read More »

Issues statement on Congressional hearing "Reviewing the Rising Price of EpiPens." Read More »

CVS Health recently announced that it is preparing to expand its dedication to the prevention of drug abuse in young persons with investments in two programs that will educate on prevention. Read More »

Maxor National Pharmacy Services LLC this week announced that an agreement has been reached for its acquisition of Pharmaceutical Specialties Inc. (PSI). Read More »

Aegerion Pharmaceuticals Inc. has appointed Remi A. Menes as its Chief Commercial Officer (CCO) effective immediately. Read More »

Bexion Pharmaceuticals LLC and the University of Cincinnati Cancer Institute (UCCI) this week announced that the first patient in the Phase I BXQ-350 trial has been dosed. Read More »

Eli Lilly and AstraZeneca recently released a joint announcement revealing that the two companies have received Fast Track designation for the AZD3293 Alzheimer’s disease development program from the U.S. Food and Drug Administration (FDA). Read More »

Zealand Pharma recently announced that Sanofi has submitted updated information for iGlarLixi’s pen delivery device to the U.S. Food and Drug Administration (FDA). Read More »

Eisai Inc. last week announced that new data on FYCOMPA (perampanel) CIII presented at the 12th European Congress on Epileptology (ECE) has shown that adjunctive use of the medication for up to two-and-a-half years has proven to deliver persistent seizure control in patients suffering from primary generalized tonic clonic (PGTC) seizures who have been poorly controlled. Read More »

Pfizer Inc. announced last week that its study to assess the safety, efficiency and immunogenicity of PF-06438179 called REFLECTIONS B537-02 has met its primary endpoint. Read More »